Company
Every investor coverage indicates participated in a round Vida Strategic Partners raised.
Companies Vida Strategic Partners acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Vida Strategic Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.
Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.
UK cancer biotech Pathios Therapeutics, backed by Canaan Partners and Brandon Capital, presented preclinical data at a US conference showing its GPR65 inhibitor PTT-3213 shrank tumors in mouse models.